Changing the Conversation: A Closer Look at the Evidence for AIRSUPRA® (albuterol 90 mcg/budesonide 80 mcg)Industry Webcast Sponsored by AstraZeneca; Not for CME/CE Credit

Please join AstraZeneca for an engaging expert-led presentation offering a closer look at the evidence for AIRSUPRA. Our expert will review evidence-based guidance, efficacy and safety data, and additional analyses from Phase 3 trials that provide further clinical perspective and may challenge your thinking.

CME/CE Information

0 Credits - Not for CME/CE Credit

Release Date: 9/16/2026

Expiration Date: 9/16/2026

Topics

Asthma

Faculty

Alexis Smith, DO

Faculty

Alexis Smith, DO

Learn More

Industry Sponsor

AstraZeneca

Fine Print

Computer System Requirements

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.

Changing the Conversation: A Closer Look at the Evidence for AIRSUPRA® (albuterol 90 mcg/budesonide 80 mcg)Industry Webcast Sponsored by AstraZeneca; Not for CME/CE Credit

CME/CE Information

Topics

Faculty

Faculty

Alexis Smith, DO

Supporters and Partners

Industry Sponsor

Fine Print

Changing the Conversation: A Closer Look at the Evidence for AIRSUPRA® (albuterol 90 mcg/budesonide 80 mcg)